Flare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.

PureTech Health is a publicly traded biopharmaceutical company that discovers, develops, and commercializes breakthrough medicines by founding and funding a network of subsidiary companies, including Celea Therapeutics.